ReviewBiomaterials2019
T cell immunotherapy enhanced by designer biomaterials.
Review in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- From bone replacement to regeneration. A biomaterials started journey.Materials today. Bio · 2026Review
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- TCR-epiDiff: solving dual challenges of TCR generation and binding prediction.Bioinformatics (Oxford, England) · 2025Article
- Article
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Review
- Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques.Frontiers in bioengineering and biotechnology · 2023Review
- Biomaterials promoteFrontiers in immunology · 2023Review
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.Tissue engineering and regenerative medicine · 2022Review
- Recent advances in surface modification of micro- and nano-scale biomaterials with biological membranes and biomolecules.Frontiers in bioengineering and biotechnology · 2022Review
- A dendritic cell-like biomimetic nanoparticle enhances T cell activation for breast cancer immunotherapy.Chemical science · 2021Article
- Nanoconfinement of microvilli alters gene expression and boosts T cell activation.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Nanoparticles for generating antigen-specific T cells for immunotherapy.Seminars in immunology · 2021Review
- Engineered immune cells with nanomaterials to improve adoptive cell therapy.Biomedical engineering letters · 2021Review
- Functional bionanomaterials for cell surface engineering in cancer immunotherapy.APL bioengineering · 2021Review
- Engineering precision nanoparticles for drug delivery.Nature reviews. Drug discovery · 2021Review
- Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapy has recently burst onto the center stage of cancer treatment and research. T lymphocyte adoptive cellular transfer (ACT), a form of cancer immunotherapy, has spawned unprecedented complete remissions for terminal patients with certain leukemias and lymphomas. Unfortunately, the successes have been overshadowed by the disappointing clinical results of ACT administered to treat solid tumors, in addition to the toxicities associated with the treatment, a lack of efficacy in a significant proportion of the patient population, and cancer relapse following the treatment. Biomaterials hold the promise of addressing these shortcomings. ACT consists of two main stages - T lymphocyte ex vivo expansion followed by reinfusion into the patient - and biomaterials can improve the efficacy of ACT at both stages. In this review, we highlight recent advances in the use of biomaterials for T lymphocyte adoptive cellular cancer immunotherapy and discuss the challenges at each stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.